The Regeneron investment is a strong strategic signal that may support the stock near-term, but the governance entrenchment provisions are a clear negative for activist and governance-focused investors. Monitor for any early lock-up waiver or Regeneron stake disclosures. The next catalyst is likely pipeline data readouts or partnership announcements.
Price Chart
Executive Summary
Parabilis Medicines completed its IPO and simultaneously closed a $75M private placement with Regeneron at a 10% discount to the IPO price, issuing 4,166,666 shares. The company also adopted a classified board, supermajority vote requirements for director removal and bylaw amendments, and exclusive forum provisions. The Regeneron investment provides a strong strategic endorsement and capital, but the governance changes entrench the board and limit shareholder rights.
Key Financial Metrics
Key Facts
- Regeneron purchased $75M of PBLS common stock at 90% of the $20.00 IPO price, or $18.00 per share.
- The private placement closed concurrently with the IPO on June 11, 2026.
- 4,166,666 shares were issued to Regeneron in the private placement.
- The company adopted a classified board with three-year staggered terms for directors.
- Directors may only be removed for cause by a 2/3 supermajority vote.
- Stockholder action by written consent is eliminated (except for preferred stock).
- Special meetings may only be called by the board, not by stockholders.
- Bylaw amendments by stockholders require a 2/3 supermajority unless the board recommends the change.
- The charter authorizes 800M shares of common stock (600M voting, 200M non-voting) and 10M shares of undesignated preferred stock.
- Exclusive forum provisions designate Delaware Chancery Court for internal corporate claims and federal district courts for Securities Act claims.
Financial Impact
$75M capital infusion at a 10% discount to the IPO price, representing a ~4.2% stake based on the 100M shares outstanding post-IPO (assuming the IPO was 16.7M shares at $20 for ~$333M gross proceeds).
Risk Factors
- Governance entrenchment may deter activist investors and could lead to a governance discount in the stock.
- Regeneron's 4.99% beneficial ownership limitation on conversion of non-voting stock could limit liquidity and voting power alignment.
- The 10% discount to IPO price for Regeneron represents immediate dilution to public IPO investors.
- Classified board and supermajority requirements make it difficult for shareholders to effect change.
Market Snapshot
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-267550 |
| Document: ck0001657677-ex10_1.htm | 0001193125-26-267550 |
| Document: ck0001657677-20260609.htm | 0001193125-26-267550 |
| Document: ck0001657677-ex3_1.htm | 0001193125-26-267550 |
| Document: 0001193125-26-267550-index-headers.html | 0001193125-26-267550 |
| Document: 0001193125-26-267550-index.html | 0001193125-26-267550 |
| Document: 0001193125-26-267550.txt | 0001193125-26-267550 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 24, 2026 2d ago | Press Release | $24.79 | awaiting T+60 | — | $25.03 (+0.97%) |
Oct 19, 2026 7d ago | Press Release | $25.35 | awaiting T+60 | — | $25.03 (−1.26%) |
Sep 15, 2026 5w ago | 8-K | $36.88 | awaiting T+60 | — | $25.03 (−32.13%) |
Sep 2, 2026 7w ago | 8-K | $40.75 | awaiting T+60 | — | $25.03 (−38.58%) |
Aug 13, 2026 10w ago | 8-K | $35.67 | awaiting T+60 | — | $25.03 (−29.83%) |
Aug 13, 2026 10w ago | Press Release | $35.67 | awaiting T+60 | — | $25.03 (−29.83%) |
Jul 22, 2026 13w ago | Insider Buy | $32.81 $22.75 | ▼ −30.66% | ▼ −34.31% | $25.03 (−23.71%) |
Jun 29, 2026 17w ago | Insider Cluster | $29.19 $33.31 | ▲ +14.11% | ▲ +10.50% | $25.03 (−14.25%) |
Jun 16, 2026 18w ago | Insider Cluster | $26.03 $36.16 | ▲ +38.92% | ▲ +36.23% | $25.03 (−3.84%) |
Jun 15, 2026 18w ago | Insider Cluster | $26.59 $36.88 | ▲ +38.70% | ▲ +36.84% | $25.03 (−5.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers